Charles Schwab’s Dyne Therapeutics DYN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $21M | Buy |
1,158,390
+7,065
| +0.6% | +$122K | ﹤0.01% | 1725 |
|
|
2025
Q4 | $22.5M | Buy |
1,151,325
+144,131
| +14% | +$2.73M | ﹤0.01% | 1679 |
|
|
2025
Q3 | $12.7M | Buy |
1,007,194
+262,123
| +35% | +$2.99M | ﹤0.01% | 1996 |
|
|
2025
Q2 | $7.09M | Buy |
745,071
+90,940
| +14% | +$1M | ﹤0.01% | 2172 |
|
|
2025
Q1 | $6.84M | Sell |
654,131
-13,321
| -2% | -$191K | ﹤0.01% | 2140 |
|
|
2024
Q4 | $15.7M | Buy |
667,452
+18,800
| +3% | +$556K | ﹤0.01% | 1818 |
|
|
2024
Q3 | $23.3M | Buy |
648,652
+47,590
| +8% | +$1.89M | ﹤0.01% | 1615 |
|
|
2024
Q2 | $21.2M | Buy |
601,062
+139,540
| +30% | +$4.05M | ﹤0.01% | 1644 |
|
|
2024
Q1 | $13.1M | Buy |
461,522
+129,954
| +39% | +$2.94M | ﹤0.01% | 1843 |
|
|
2023
Q4 | $4.41M | Buy |
331,568
+6,197
| +2% | +$60.5K | ﹤0.01% | 2367 |
|
|
2023
Q3 | $2.92M | Buy |
325,371
+40,250
| +14% | +$434K | ﹤0.01% | 2478 |
|
|
2023
Q2 | $3.21M | Buy |
285,121
+57,537
| +25% | +$679K | ﹤0.01% | 2399 |
|
|
2023
Q1 | $2.62M | Sell |
227,584
-558
| -0.2% | -$7.25K | ﹤0.01% | 2450 |
|
|
2022
Q4 | $2.64M | Buy |
228,142
+5,708
| +3% | +$66K | ﹤0.01% | 2476 |
|
|
2022
Q3 | $2.83M | Buy |
222,434
+43,281
| +24% | +$496K | ﹤0.01% | 2478 |
|
|
2022
Q2 | $1.23M | Sell |
179,153
-13,324
| -7% | -$91.8K | ﹤0.01% | 2717 |
|
|
2022
Q1 | $1.86M | Buy |
192,477
+3,918
| +2% | +$33.4K | ﹤0.01% | 2670 |
|
|
2021
Q4 | $2.24M | Buy |
188,559
+4,376
| +2% | +$61.5K | ﹤0.01% | 2668 |
|
|
2021
Q3 | $2.99M | Buy |
184,183
+32,557
| +21% | +$577K | ﹤0.01% | 2601 |
|
|
2021
Q2 | $3.19M | Buy |
151,626
+29,134
| +24% | +$548K | ﹤0.01% | 2564 |
|
|
2021
Q1 | $1.9M | Buy |
122,492
+40,216
| +49% | +$778K | ﹤0.01% | 2679 |
|
|
2020
Q4 | $1.73M | Buy |
+82,276
| New | +$1.63M | ﹤0.01% | 2629 |
|
Other funds holding DYN
AVLSA
OAG
VCM
PA
FIS